STSS earnings analysis
What we found in STSS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Sharps Technology reported a significant net loss of approximately $86 million for Q1 2026, primarily driven by unrealized losses on their Solana (SOL) holdings. Despite a notable increase in revenues to $192,780 from syringe sales, total operating expenses surged, underscoring persistent financial challenges amid a strategic pivot towards digital commodities.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Sizeable net loss
- The company recorded a net loss of $86,239,232 for Q1 2026, compared to a profit of $1,928,834 in the same period last year.
- Revenue growth
- Revenue from syringe sales was $192,780, a notable growth from $0 in Q1 2025.
- Strong staking revenue
- Net staking revenue amounted to $3,134,109, reflecting success in the digital commodity segment.
- Increased cash reserves
- Cash balance improved to $12,320,547 from $10,382,745 at year-end 2025.
- R&D and G&A expense increase
- R&D expenses reached $137,097, up from none in the prior year; G&A expenses increased by $3.69 million to $5,053,320.
- Improved working capital position
- Working capital rose to $16,160,964 in Q1 2026, up from $14,187,484 at the end of 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Significant unrealized losses
- The company experienced unrealized losses on digital commodity investments totaling $70,846,202.
- High operational expenses
- Total operating expenses rose to $89,390,281 for the quarter, sharply contrasting with Q1 2025 expenses of $1,364,295.
- Volatility in digital asset market
- Risks associated with the fluctuating value of Solana and potential regulatory challenges in the digital commodities market.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-86.24
- Segment
- Medical Device
- Segment
- Digital Commodities
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
What came before.
- 10-K · March 31, 2026
- Sharps Technology materially pivoted its corporate strategy in 2025, completing a Private Investment in Public Equity (PIPE) of approximately $400 million on August 28, 2025 and allocating the principal holding of its…
- 10-Q · May 15, 2025
- Sharps Technology reported Q1 2025 net revenue of $0 and GAAP net income of $1,928,834 (EPS $38.62) versus a net loss of $(982,386) (EPS $(347.50)) in Q1 2024, driven primarily by a $4,618,889 fair value gain on warrant…
- 10-Q · November 14, 2024
- Sharps Technology remains a pre-revenue medical device company: revenue for the period was $0 and the company reported a Q3 net loss of $1,685,060 (−$1.27 per share), an improvement from a Q3 2023 loss of $2,022,344…
- 10-K · March 29, 2024
- Sharps Technology is an early-stage medical device company commercializing ultra-low waste safety syringes. The company reports it "has not generated any revenue to date," incurred net losses of $9,841,638 in 2023 (and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing STSS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever